Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Aug 14;4(8):e6638.
doi: 10.1371/journal.pone.0006638.

Hypothalamic neuroendocrine functions in rats with dihydrotestosterone-induced polycystic ovary syndrome: effects of low-frequency electro-acupuncture

Affiliations

Hypothalamic neuroendocrine functions in rats with dihydrotestosterone-induced polycystic ovary syndrome: effects of low-frequency electro-acupuncture

Yi Feng et al. PLoS One. .

Abstract

Adult female rats continuously exposed to androgens from prepuberty have reproductive and metabolic features of polycystic ovary syndrome (PCOS). We investigated whether such exposure adversely affects estrous cyclicity and the expression and distribution of gonadotropin-releasing hormone (GnRH), GnRH receptors, and corticotrophin-releasing hormone (CRH) in the hypothalamus and whether the effects are mediated by the androgen receptor (AR). We also assessed the effect of low-frequency electro-acupuncture (EA) on those variables. At 21 days of age, rats were randomly divided into three groups (control, PCOS, and PCOS EA; n = 12/group) and implanted subcutaneously with 90-day continuous-release pellets containing vehicle or 5alpha-dihydrostestosterone (DHT). From age 70 days, PCOS EA rats received 2-Hz EA (evoking muscle twitches) five times/week for 4-5 weeks. Hypothalamic protein expression was measured by immunohistochemistry and western blot. DHT-treated rats were acyclic, but controls had regular estrous cycles. In PCOS rats, hypothalamic medial preoptic AR protein expression and the number of AR- and GnRH-immunoreactive cells were increased, but CRH was not affected; however, GnRH receptor expression was decreased in both the pituitary and hypothalamus. Low-frequency EA restored estrous cyclicity within 1 week and reduced the elevated hypothalamic GnRH and AR expression levels. EA did not affect GnRH receptor or CRH expression. Interestingly, nuclear AR co-localized with GnRH in the hypothalamus. Thus, rats with DHT-induced PCOS have disrupted estrous cyclicity and an increased number of hypothalamic cells expressing GnRH, most likely mediated by AR activation. Repeated low-frequency EA normalized estrous cyclicity and restored GnRH and AR protein expression. These results may help explain the beneficial neuroendocrine effects of low-frequency EA in women with PCOS.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Vaginal smears and estrous cycle patterns of control, PCOS, and PCOS EA rats.
A) Representative vaginal smears from a normal cycling control rat at different stages in the estrous cyclediestrus (top left), proestrus (top right), estrus (middle left), and metestrus (middle right). Representative hematoxylin eosin stained vaginal smear from a PCOS rat exhibiting predominantly leukocytes, the main cell type during diestrus stage (bottom left). Representative vaginal smear from a PCOS EA rat exhibiting epithelial kerotinocytes, the main cell type during estrus stage (bottom right). Scale bar, 100 µm (top left). B) Estrous cycle patterns at 70–95 days of age (i.e., 49–84 days after pellet implantation) in four representative rats from each group. P, proestrus; E, estrus; M, metestrus; and D, diestrus.
Figure 2
Figure 2. Western blot analysis of AR, p21, and c-Fos protein expression in the hypothalamus.
Regulation of AR, p21, and c-Fos protein expression in the hypothalamus in the control (n = 7), PCOS (n = 6), and PCOS EA (n = 6) groups. Top: total protein (50 µg) was isolated and used for western blot analysis. The blot is representative of each run with independent samples. Bottom: densitometric analysis of the levels of AR, p21, and c-Fos protein expression. Equal sample loading was confirmed by Coomassie blue staining. Relative levels of AR, p21, and c-Fos proteins were expressed as a ratio of densitometric value to whole proteins in Coomassie blue–stained gels. Values are mean±SEM of two independent experiments (n = 3 pools/group). ***p<0.001, **p<0.01 vs. control; ##p<0.05 vs. PCOS.
Figure 3
Figure 3. AR-ir cells in the medial preoptic area (MPO) and ventromedial hypothalamus (VMH).
A) Light micrographs of AR-ir cells, detected with polyclonal antibody as described in Materials and Methods. Scale bar, 100 µm. B) Quantification of AR-ir cells in the different regions in the control (n = 5), PCOS (n = 6), and PCOS EA (n = 6) groups. Values are mean±SEM. **p<0.01 vs. control; ##p<0.01 vs. PCOS, #p<0.05 vs. PCOS.
Figure 4
Figure 4. GnRH-ir cells in the rostral MS, MPO, and HDB of the hypothalamus.
A) Light micrographs of GnRH-ir cells, detected with polyclonal antibody as described in Materials and Methods. Scale bar, 100 µm. B) Quantification of GnRH-ir cells in the different regions in the control (n = 5), PCOS (n = 6), and PCOS EA (n = 6) groups. Values are mean±SEM. *p<0.05 vs. control; #p<0.05 vs. PCOS. C) Immunoprecipitation and western blot (WB) of GnRH protein in the hypothalamus.
Figure 5
Figure 5. GnRH-R-ir cells in the rostral MS, and nucleus of the HDB of the hypothalamus and pituitary (Pit).
A) Light micrographs of the GnRH-R-ir cells, detected with polyclonal antibodies as described in Materials and Methods. Scale bar, 100 µm. B) Quantification of GnRH-R cells in the control (n = 5), PCOS (n = 6), and PCOS EA (n = 6) groups. Values are mean±SEM. *p<0.05 vs. control; #p<0.05 vs. PCOS. C) Western blot of GnRH-R protein in the hypothalamus. Total protein (50 µg) was isolated and used for western blot analysis. The blot is representative of two essentially similar experiments, each run with independent samples. Densitometric analysis of GnRH-R protein expression in two independent experiments. Equal sample loading was confirmed by Coomassie blue staining. Relative levels of GnRH-R proteins were expressed as a ratio of densitometric value to whole proteins in Coomassie blue–stained gels. Data are expressed as ADU; values are the mean±SEM of two independent experiments (n = 3 pools/group). *p<0.05 vs. control.
Figure 6
Figure 6. CRH-ir cells in the PVN and MPO in control, PCOS and PCOS EA rats.
A) Light micrographs of CRH-ir cells, detected with polyclonal antibodies as described in Materials and Methods. Scale bar, 100 µm. B) Quantification of CRH-ir cells in the different regions in the control (n = 5), PCOS (n = 6), and PCOS EA (n = 6) groups. Values are mean±SEM. C) Protein samples were isolated from the hypothalamus of control, PCOS, and PCOS EA rats. Total protein (50 µg) was isolated and used for western blot analysis. The blot is representative of two essentially similar experiments, each run with independent samples. Densitometric analysis of CRH protein expression in two independent experiments. Equal sample loading was confirmed by Coomassie blue staining. Relative levels of CRH proteins were expressed as a ratio of densitometric value to whole proteins in Coomassie blue–stained gels. Data are expressed as ADU. Values are mean±SEM of two independent experiments (n = 3 pools/group).
Figure 7
Figure 7. Co-localization of AR, GnRH, and CRH in MPO neurons, determined by dual-fluorescence immunohistochemistry and confocal laser-scanning microscopy.
A) Main distribution of AR, GnRH, and CRH in control female rat brain (3v = third ventricle). Adapted from reference . B–D) Co-localization of AR, GnRH, CRH, and NeuN immunoreactivity in MPO neurons. E) Co-localization of rabbit polyclonal AR antibody and mouse monoclonal AR antibody in hypothalamic MPO. F and G) Co-localization of mouse monoclonal AR antibody with GnRH or CRH immunoreactivity in hypothalamic MPO neurons. In panels B–G, arrows indicate co-localization. Scale bars, 100 µm.

References

    1. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet. 2007;370:685–697. - PubMed
    1. Hayes FJ, Taylor AE, Martin KA, Hall JE. Use of a gonadotropin-releasing hormone antagonist as a physiologic probe in polycystic ovary syndrome: assessment of neuroendocrine and androgen dynamics. J Clin Endocrinol Metab. 1998;83:2343–2349. - PubMed
    1. Barontini M, Garcia-Rudaz MC, Veldhuis JD. Mechanisms of hypothalamic-pituitary-gonadal disruption in polycystic ovarian syndrome. Arch Med Res. 2001;32:544–552. - PubMed
    1. Foecking EM, Szabo M, Schwartz NB, Levine JE. Neuroendocrine consequences of prenatal androgen exposure in the female rat: absence of luteinizing hormone surges, suppression of progesterone receptor gene expression, and acceleration of the gonadotropin-releasing hormone pulse generator. Biol Reprod. 2005;72:1475–1483. - PubMed
    1. Rivest S, Rivier C. The role of corticotropin-releasing factor and interleukin-1 in the regulation of neurons controllin reproductive functions. Endocrine Rev. 1995;16:177–199. - PubMed

Substances